Sweden

Calliditas Therapeutics AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Jefferies LLC

Deal Size: $90.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 05, 2020

Details:

Calliditas intends to use the net proceeds for the purposes of funding of its ongoing Phase 3 clinical trial and related trials of Nefecon, pre-commercialization and, if approved, commercialization activities for Nefecon and development of additional product candidates.

Calliditas Therapeutics AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sweden's Calliditas Seeks $75M IPO Haul to Bring Its Oral Steroid to Patients with an Orphan Kidney Disease

Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $75.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 14, 2020

Details:

The net proceeds will be used to advance clinical and commercial developments of Calliditas's lead drug, Nefecon, an oral formulation of the corticosteroid budesonide.

Calliditas Therapeutics AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic

Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Calliditas does not anticipate a significant impact of the Covid-19 pandemic on the ongoing clinical activities related to NefIgArd, the company's pivotal Phase 3 IgA nephropathy trial.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Calliditas Therapeutics AB

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Calliditas Therapeutics AB

Sweden's Calliditas Seeks $75M IPO Haul to Bring Its Oral Steroid to Patients with an Orphan Kidney Disease

Calliditas Therapeutics AB

Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic